02806nas a2200289 4500000000100000008004100001260003700042653002300079653001900102653002900121653002500150653001000175100001500185700001200200700001900212700001600231700001800247700001300265700001300278700001500291245013000306856009900436300000900535490000700544520195100551022001402502 2024 d bPublic Library of Science (PLoS)10acost-effectiveness10aVector control10aMass drug administration10aLymphatic filariasis10aIndia1 aShepard DS1 aLwin AK1 aPulikkottil SI1 aKalimuthu M1 aArunachalam N1 aTyagi BK1 aWhite GB1 aFischer PU00aCost-effectiveness of vector control for supplementing mass drug administration for eliminating lymphatic filariasis in India uhttps://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0011835&type=printable a1-240 v183 a

Background/Methodology: Despite progress using mass drug administration (MDA), lymphatic filariasis (LF) remains a major public health issue in India. Vector control could potentially augment MDA towards LF elimination. We conducted a cost-effectiveness analysis of MDA alone and MDA together with vector control single (VCS) modality or vector control integrated (VCI) modalities. Data came from historical controls and a three-arm cluster randomized trial of 36 villages at risk of LF transmission in Tamil Nadu, India. The arms were: MDA alone (the standard of care); MDA plus VCS (expanded polystyrene beads covering the water surface in wells and cesspits to suppress the filariasis vector mosquito Culex quinquefasciatus); and MDA plus VCI (VCS plus insecticidal pyrethroid-impregnated curtains [over windows, doors, and eaves). Economic costs in 2010 US$ combined government and community inputs from household to state levels. Outcomes were controlled microfilaria prevalence (MfP) and antigen prevalence (AgP) to conventional elimination targets (MfP<1% or AgP<2%) from 2010 to 2013, and modeled disability adjusted life years (DALYs) averted.

Principal findings: The estimated annual economic cost per resident was US$0.53 for MDA alone, US$1.02 for VCS, and US$1.83 for VCI. With MDA offered in all arms, all arms reduced LF prevalence substantially from 2010 to 2013. MDA proved highly cost effective at $112 per DALY averted, a very small (8%) share of India’s then per capita Gross Domestic Product. Progress towards elimination was comparable across all three study arms.

Conclusions: The well-functioning MDA program proved effective and very cost-effective for eliminating LF, leaving little scope for further improvement. Supplementary vector control demonstrated no statistically significant additional benefit on MfP or AgP in this trial.

 a1935-2735